AI assistant
Cardiff Oncology, Inc. — Director's Dealing 2017
Sep 6, 2017
33967_dirs_2017-09-06_eb8918a2-1d55-4ea3-9dee-5b7e05265508.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Trovagene, Inc. (TROV)
CIK: 0001213037
Period of Report: 2017-09-02
Reporting Person: Tennant Stanley (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-09-02 | Common Stock | M | 8484 | — | Acquired | 217878 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-09-02 | Restricted Stock Units | $ | M | 8484 | Disposed | Common Stock (8484) | Direct |
Footnotes
F1: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 8,484 restricted stock units, all of which vested on September 2, 2017. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017.
F2: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock.
F3: On January 2, 2017, the reporting person was granted 8,484 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4.